Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy

Abstract

Iron chelation therapies (ICTs) can help eliminate iron surplus in erythrocyte transfusion-dependent (TD) patients with myelofibrosis (MF). The study assessed adjusted incidence rate ratios (aIRRs) of MF-related complications and resource utilization (RU) and adjusted mean monthly inpatient cost differences in patients with TD MF treated with versus without ICT (ICT+ vs. ICT−) using data from two healthcare claims databases. Patients with ≥ 2 MF International Classification of Diseases, 9th Revision (ICD-9) diagnosis codes ≥ 30 days apart were included. Among 571 patients with TD MF, 103 (18%) were ICT+ and 468 (82%) were ICT−. ICT+ patients had lower rates of thrombocytopenia (aIRR: 0.55; p < 0.001), pancytopenia (0.53; p < 0.001), emergency room visits (0.84 [95% confidence interval: 0.74–0.96]) and inpatient stays (0.75 [0.64–0.87]), but higher rates of outpatient visits (1.21 [1.18–1.23]). Adjusted mean complication-related inpatient cost difference per month was lower in ICT+ patients (−$1804 [$570]; p = 0.004). ICT+ patients had significantly lower rates of acute care, but higher rates of outpatient care.

Keywords::

• Myelofibrosis
• transfusion dependent
• iron chelation therapy
• medical resource utilization
• economic cost

Acknowledgement

This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Supplementary material available online

Appendix Tables showing ICD-9 codes, and further study design and methods.

Supplementary Appendix Tables I–III.